Akebia Therapeutics (AKBA) Receivables (2016 - 2025)
Historic Receivables for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $69.3 million.
- Akebia Therapeutics' Receivables rose 10380.35% to $69.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.3 million, marking a year-over-year increase of 10380.35%. This contributed to the annual value of $36.4 million for FY2024, which is 1465.17% down from last year.
- As of Q3 2025, Akebia Therapeutics' Receivables stood at $69.3 million, which was up 10380.35% from $78.2 million recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Receivables peaked at $138.6 million during Q2 2022, and registered a low of $19.1 million during Q1 2023.
- Its 5-year average for Receivables is $50.8 million, with a median of $38.8 million in 2021.
- In the last 5 years, Akebia Therapeutics' Receivables soared by 178718.29% in 2021 and then crashed by 8550.29% in 2023.
- Quarter analysis of 5 years shows Akebia Therapeutics' Receivables stood at $70.7 million in 2021, then crashed by 40.31% to $42.2 million in 2022, then grew by 1.04% to $42.6 million in 2023, then decreased by 14.65% to $36.4 million in 2024, then surged by 90.45% to $69.3 million in 2025.
- Its Receivables was $69.3 million in Q3 2025, compared to $78.2 million in Q2 2025 and $63.1 million in Q1 2025.